Literature DB >> 2506045

Conditions required for the antibacterial activity of zidovudine.

C S Lewin1, S G Amyes.   

Abstract

In a study to determine the conditions required for its antibacterial activity, zidovudine was found to be bactericidal against Escherichia coli and Salmonella typhimurium in nutrient broth over 6 h. Zidovudine was also found to be active against ten clinical isolates of Salmonella and Escherichia coli at 1 mg/l, which is a clinically achievable concentration of the drug. Bacterial protein synthesis was required for the bactericidal activity of zidovudine against both Escherichia coli and Salmonella typhimurium. Zidovudine was found to be inactive against non-dividing bacteria, as it was unable to kill bacteria of either species when they were suspended in PBS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506045     DOI: 10.1007/bf01963765

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

Review 1.  Strategies for antiviral therapy in AIDS.

Authors:  H Mitsuya; S Broder
Journal:  Nature       Date:  1987 Feb 26-Mar 4       Impact factor: 49.962

2.  Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U).

Authors:  L P Elwell; R Ferone; G A Freeman; J A Fyfe; J A Hill; P H Ray; C A Richards; S C Singer; V B Knick; J L Rideout
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  Bactericidal mechanisms of ofloxacin.

Authors:  C S Lewin; J T Smith
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

4.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

5.  Trimethoprim resistance determinants encoding a dihydrofolate reductase in clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci.

Authors:  J M Tennent; H K Young; B R Lyon; S G Amyes; R A Skurray
Journal:  J Med Microbiol       Date:  1988-05       Impact factor: 2.472

6.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

7.  Trimethoprim action and its analogy with thymine starvation.

Authors:  S G Amyes; J T Smith
Journal:  Antimicrob Agents Chemother       Date:  1974-02       Impact factor: 5.191

  7 in total
  4 in total

1.  In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana.

Authors:  Kathleen M Powis; Laura Smeaton; Michael D Hughes; Esther A Tumbare; Sajini Souda; Jennifer Jao; Kathleen E Wirth; Joseph Makhema; Shahin Lockman; Wafaie Fawzi; Max Essex; Roger L Shapiro
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

2.  In vitro activities of nucleoside analog antiviral agents against salmonellae.

Authors:  S J Sperber; E L Feibusch; A Damiani; M P Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

3.  Intracellular activity of zidovudine (3'-azido-3'-deoxythymidine, AZT) against Salmonella typhimurium in the macrophage cell line J774-2.

Authors:  J L Herrmann; P H Lagrange
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections.

Authors:  S M S Ng; J S P Sioson; J M Yap; F M Ng; H S V Ching; J W P Teo; R Jureen; J Hill; C S B Chia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-10       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.